ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
New Indication Approval for Ribociclib: A Game Changer for CDK4/6 Inhibitors
October 18, 2024Recently, the FDA officially approved Novartis's ribociclib, in combination with aromatase inhibitors (AI), for the adjuvant treatment of hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)
Pharma Sources Insight January 2025
